Search

DexCom Inc

Cerrado

SectorSanidad

72.43 -3.22

Resumen

Variación precio

24h

Actual

Mínimo

74.01

Máximo

76.18

Métricas clave

By Trading Economics

Ingresos

-68M

200M

Ventas

-68M

1.2B

P/B

Media del Sector

32.909

62.58

BPA

0.56

Margen de beneficios

16.738

Empleados

11,000

EBITDA

-52M

337M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.37% upside

Dividendos

By Acuity

Próximas Ganancias

30 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

5.5B

29B

Apertura anterior

75.65

Cierre anterior

72.43

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

323 / 340 Clasificación en Healthcare

DexCom Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 jul 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Comparación entre iguales

Cambio de precio

DexCom Inc previsión

Precio Objetivo

By TipRanks

12.37% repunte

Estimación a 12 Meses

Media 84 USD  12.37%

Máximo 112 USD

Mínimo 64 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para DexCom Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

22 ratings

20

Comprar

1

Mantener

1

Vender

Sentimiento

By Acuity

323 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.